Pharmacokinetics, pharmacodynamics, and safety of izuforant, an H4R inhibitor, in healthy subjects: A phase I single and multiple ascending dose study

Documenti analoghi

• Population Pharmacokinetic–Pharmacodynamic Modeling of Granulocyte Colony‐Stimulating Factor to Optimize Dosing and Timing for CD34+ Cell Harvesting
  di: Xu Jiang, et al.
  Pubblicazione: (2025)
• Pharmacokinetics, pharmacodynamics, and safety of frunexian in healthy Chinese volunteer adults: A randomized dose‐escalation phase I study
  di: Jia‐yu Zhang, et al.
  Pubblicazione: (2024)
• Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers
  di: Tianxing Liu, et al.
  Pubblicazione: (2024)
• Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with Caucasian data
  di: Huijun Chen, et al.
  Pubblicazione: (2024)
• Randomized, double‐blind, phase 1a single‐ascending dose and food effect studies assessing safety and pharmacokinetics of EC5026 in healthy volunteers
  di: William K. Schmidt, et al.
  Pubblicazione: (2024)